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Background: Congenital hyperinsulinism leads to unregulated insulin secretion and hypoglycemia. Diagnosis can
be difficult and genetic testing may be warranted.
Case: This patient initially presented at 11 months with seizure activity secondary to severe hypoglycemia. Her
diagnostic evaluation included genetic studies, which confirmed congenital hyperinsulinism. A novel combination
of mutations in the ABCC8 gene leading to diffuse, diazoxide-unresponsive congenital hyperinsulinism was
identified. Mutation analysis of ABCC8 showed three variants (R1215W – paternal, pathogenic; W739C – maternal,
variant of unknown significance; R1393L – maternal, variant of unknown significance). Her clinical course continues
to be complicated by severe, refractory hypoglycemia at age 3 years.
Conclusion: We describe a novel compound heterozygous mutation leading to diffuse, diazoxide-unresponsive
congenital hyperinsulinism. This case illustrates challenges associated with diagnosing and managing congenital
hyperinsulinism and the importance of genetic testing.
Keywords: Congenital hyperinsulinism, ABCC8, Octreotide, Diazoxide-unresponsiveBackground
Congenital hyperinsulinism (CHI) leads to hypoglycemia
in infants and children due to inappropriately elevated in-
sulin levels. Mutations leading to CHI have been described
in nine genes [1]. The most common mutations occur in
ABCC8 and KCNJ11, which encode for the ATP-sensitive
potassium (KATP) channel present on the beta-cell plasma
membrane. During normal glucose-stimulated insulin se-
cretion, the KATP channel closes in response to an increase
in the energy potential of the beta-cell. Closure of this
channel results in depolarization of the beta-cell plasma
membrane leading to calcium influx into the beta-cell and
insulin secretion. Certain mutations in ABCC8 and
KCNJ11 lead to defective KATP channels that are either un-
able to open or cannot localize to the plasma membrane
[2]. Defective channels lead to continued depolarization of
the plasma membrane and insulin secretion regardless of
the plasma glucose level. Patients with these mutations* Correspondence: cassie.brady@vanderbilt.edu
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[1, 3]. Diazoxide is a KATP channel agonist which keeps the
channel in an open state resulting in the suppression of in-
sulin secretion [4]. Severe forms of CHI can lead to
complete destruction of channel activity and are therefore
unresponsive to diazoxide [2]. Inheritance of ABCC8 and
KCNJ11 mutations occurs in either a dominant or reces-
sive fashion [1]. These mutations, dependent on inherit-
ance pattern, may lead to focal or diffuse disease
histologically (i.e. localized islet cell abnormalities versus
effects throughout pancreas). Homozygous or compound
heterozygous recessive mutations are associated with dif-
fuse disease, and are typically managed medically or with
near–total pancreatectomy, as indicated.
The diagnosis of CHI can be made during a fasting chal-
lenge. At the time of hypoglycemia (glucose <50 mg/dL
(2.775 mmol/L)) [2, 3], a blood sample (“critical sample”)
is obtained to assess the presence or absence of key meta-
bolic indices and counter-regulatory hormones which
serve as alternative fuels and stimulants to raise serum
glucose. Often, the fasting challenge does not yield con-
firmatory or clear diagnostic evidence of CHI and a repeaticle distributed under the terms of the Creative Commons Attribution License
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recommended to assess for the common CHI-causing
mutations in patients with a known or suspected diagnosis
of hyperinsulinism.
Once CHI is confirmed, defining the extent of disease is
a critical next step to determine ideal intervention. Previ-
ously, imaging studies such as ultrasound, computed tom-
ography, and magnetic resonance imaging have been
implemented for the purpose of distinguishing focal from
diffuse disease. However, these studies have not been
shown to be effective for this purpose. The radiotracer
18fluoro-L- dihydroxyphenylalanine (18 F-DOPA), which
concentrates in insulin-secreting beta cells of the pan-
creas, has been used in specialized CHI care centers for
the past decade to classify disease. In the largest series, the
specificity of this imaging technique to detect focal disease
was 96 % [5].
This case demonstrates a novel compound heterozy-
gous mutation causing CHI, the natural history of this
mutation, and the associated challenges in management.
This case also outlines the pitfalls of interpreting insulin
levels at the time of hypoglycemia and emphasizes the
importance of genetic testing in this setting.
Case presentation
An 11-month-old African-American female presented to
neurology due to seizure-like activity. She was a former
term infant with a birthweight of 3.714 kg. At presentation
she weighed 9.6 kg (56th%) and was 77 cm (89th%) tall.
During her evaluation, a glucose value of 38 mg/dL
(1.998 mmol/L) and bicarbonate of 24 mmol/L were noted.
During a subsequent fasting challenge, her serum glu-
cose decreased to 32 mg/dL (1.776 mmol/L) within
5.5 h. The results of the critical sample are presented in
Table 1. Specifically, her insulin level was appropriately
low, while her beta-hydroxybutyrate (BOHB) was min-
imally elevated, and free fatty acids were inappropriately
within the normal range. Additionally, her growth hor-
mone was low. All other laboratory results including
ammonia, *urine organic acids, *serum amino acids, andTable 1 Fasting challenge results
Test name (Normal range) Laboratory
result
IGFBP-1 (ng/mL) (5–9 years: 15–95; no reference range
for patients <5 years)
61
Insulin (<2-13 μIU/mL fasting) 0.2
Glucose (>70 mg/dL/3.885 mmol/L) 32/1.776
C-peptide (0.8-3.5 ng/mL) 0.5
BOHB (0–3.0 mg/dL) 4.3
(0.41 mmol/L)
Free Fatty Acids (0.5-0.9 mmol/L) 0.46
Growth Hormone (>7 ng/mL) 3*acylcarnitine profile were normal (*drawn in the fed
state). A glucagon stimulation to assess glycemic re-
sponse at the time of hypoglycemia was attempted but
was unsuccessful. Based on the critical sample results,
she was thought to have growth hormone deficiency and
was started on growth hormone therapy. She was dis-
charged after several inpatient days with improved
glucose levels.
In the interim, the insulin-like growth factor-1 (IGF-1)
(prior to growth hormone therapy) resulted at 105.7 ng/mL
(approximately the 80th% for age and sex), and insulin-
like growth factor binding protein-3 (IGFBP-3) was
2800 ng/mL (above the mean for age and sex). While at
home, she was noted to have a glucose of 19 mg/dL
(1.0545 mmol/L) despite growth hormone therapy.
Given the severity of her hypoglycemia, she was re-
admitted for further assessment. An arginine/clonidine
growth hormone stimulation test done after discontinu-
ation of growth hormone revealed a peak growth hor-
mone level of 7.9 ng/dL (radioimmunoassay). In the
setting of continued hypoglycemia despite growth hor-
mone therapy, her critical sample obtained at her initial
admission was reviewed and determined to be concern-
ing for CHI. Therefore genetic studies for CHI were
sent (Athena Diagnostics, Worcester, Massachusetts).
While genetic studies were pending, diazoxide treat-
ment was initiated and titrated to 15 mg/kg/day divided
three times daily. However, she continued to have
hypoglycemia. After one week of diazoxide therapy,
octreotide was added. Octreotide was increased to 15
mcg/kg/day, with subsequent improvement but not reso-
lution of hypoglycemia. Frequent feeds and uncooked
cornstarch were implemented to avert hypoglycemia.
Her hyperinsulinism was deemed diazoxide-unresponsive
and diazoxide was discontinued.
Mutational analysis confirmed a diagnosis of CHI as
three variants in ABCC8 were identified (Table 2). The
R1215W variant was found to be paternally-inherited
while the W739C and R1393L variants were maternally
inherited. The paternal change was a known mutation
described previously (at Children’s Hospital of Philadel-
phia) in a patient with diffuse disease. In this previously
described patient, the inheritance pattern was thought to
be recessive, given a normal maternal ABCC8 gene copy.
In our patient, the significance of the maternal variants
was unclear as they had not been previously described inTable 2 Genetic results (ABCC8 Mutation)
Mutation Inheritance Interpretation
c. R1215W Paternal Pathogenic
c. W739C Maternal VUS
c. R1393L Maternal VUS
VUS variant of unknown significance
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predict focal versus diffuse disease pathology based on
mutational analysis alone.
Our patient was transferred to Children’s Hospital of
Philadelphia for an 18-fluoro L-3, 4-dihydroxyphenylala-
nine positron emission tomography (18-F-DOPA-PET)
scan. There was no focal uptake of isotope by the pancreas
(Fig. 1), which suggested, but did not confirm diffuse dis-
ease. A pancreatic biopsy was subsequently recommended
in order to further delineate her pathology, but was de-
clined by the family. A gastrostomy tube was placed for
enteral dextrose administration (overnight glucose infu-
sion rate (GIR) of 7 mg/kg/min).
Over several months, the child has continued to
have intermittent, daily hypoglycemia despite adjust-
ments of her treatment regimen. The GIR of her
fluids has been gradually increased. Her current treat-
ment regimen at age 3 years consists of octreotide 20
mcg/kg/day divided three times daily and overnight
dextrose (14 h, GIR of 9 mg/kg/min) through her
gastrostomy tube. She continues to have daytime
hypoglycemia [glucose <70 mg/dL (3.885 mmol/L)].
Speech delay that was noted shortly after diagnosis
persists despite therapy. Considering her disease and
failure of medical management, a near-total pancrea-
tectomy may be necessary to achieve normal blood
glucose levels. Other treatment options that are also
being considered include continuous glucagon via an
insulin pump [6, 7] and continuous octreotide via an
insulin pump [8]. These treatments have not been
pursued based on parental requests.Fig. 1 Results of F-Dopa PET Scan. This image demonstrates the results of
no evidence of focal tracer uptake on this image, suggesting diffuse diseas
exclude a focal lesionConclusions
This case reveals a new compound heterozygous mutation
in ABCC8 that leads to diffuse, diazoxide-unresponsive
CHI. It highlights the severity of disease due to this com-
bination of mutations and the difficulty of diagnosis and
management.
To diagnose CHI, laboratory tests known as the “critical
sample”, are utilized and include: plasma glucose, plasma
insulin, c-peptide, insulin-like growth factor binding
protein-1 (IGFBP-1), BOHB, free fatty acids, ammonia,
lactate, pyruvate, acylcarnitine profile, free and total carni-
tine, organic acids (urine), growth hormone, and cortisol
[3]. The diagnosis of CHI can be made in the setting of
hypoglycemia when elevated insulin levels are present with
suppression of BOHB and free fatty acids. Often, the initial
fasting challenge does not yield confirmatory or clear diag-
nostic evidence of CHI and repeat fasting evaluations may
be necessary.
In the critical sample, insulin and c-peptide levels help
to establish the presence of inappropriate elevations in
insulin and to distinguish between excess endogenous
and exogenous insulin, respectively. Interpretation of in-
sulin levels at the time of hypoglycemia can be difficult,
as evidenced by this case. Insulin levels may be ele-
vated, decreased, or normal [9]. This may be due to
periodic release of insulin [3], insulin degrading en-
zymes in hemolyzed blood samples [9–11], insulin
antibodies [12], and rapid hepatic clearance [9, 13]. At
room temperature, research shows that >90 % of insu-
lin can be degraded due to massive hemolysis which
induces degrading enzymes [11]. Maintaining theour patient’s F-Dopa PET scan. The pancreas is circled in black. There is
e. However the finding of diffuse uptake on F-Dopa PET scan does not
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grading enzyme activity [11], however this can make
critical sample collection more difficult. Interfering in-
sulin antibodies may also lead to falsely low insulin
levels as demonstrated in immunoradiometric assays
and electrochemiluminescent assays in prior reports
[12]. Insulin is also rapidly degraded by the body at a
rate of 2 percent per minute with about 50 % removed
by the liver [13, 9]. These issues may have played a role
in our patient’s decreased insulin level on her fasting
challenge.
Another important indicator of hyperinsulinism is
the glycemic response to glucagon at the time of
hypoglycemia [14]. A glucose rise after glucagon of
greater than 30 mg/dL (1.665 mmol/L) may reflect hy-
perinsulinism with a sensitivity of 91 % and specificity
of 93 % [14, 9]. This glycemic excursion after glucagon
reflects the suppressive effects of insulin on the release
of glycogen stores from the liver. In our patient’s
evaluation, the glucagon challenge was not completed
in a way that it would have been interpretable.
The fasting challenge is an important opportunity to ob-
tain and interpret other counter-regulatory mechanisms
that maintain euglycemia. Elevation in BOHB is a measure
of appropriate ketogenesis during fasting. BOHB values
less than 2.7 mmol/liter (28.1 mg/dL) during hypoglycemia
have a reported sensitivity and specificity of 100 % in
hyperinsulinemia induced by an insulinoma [9, 15]. The
patient in this case had a relatively low BOHB value, which
may have been an indicator of high insulin levels. Growth
hormone and cortisol act as counter-regulatory hormones
to increase lipolysis and gluconeogenesis, respectively.
Growth hormone and cortisol are expected to be increased
during hypoglycemia if these hormonal systems are intact
[16]. The child in this case was started on growth hormone
due to the low value at the time of hypoglycemia. How-
ever, decreased growth hormone and cortisol levels at the
time of hypoglycemia are not diagnostic of deficiencies,
and 65 % of children in a study by Kelly et al. were mis-
diagnosed with growth hormone deficiency during a fast-
ing challenge [17]. Our patient subsequently had a normal
growth hormone response during further evaluation.
Shortly after diagnosis in our patient’s clinical course, it
became evident that the CHI was likely diazoxide-
unresponsive. Diazoxide-unresponsive CHI is typically
due to defects in the KATP channel [18]. However genetic
analysis and determination of inheritance pattern is ex-
tremely helpful for both prediction of disease pathology
and response to therapy. Inheritance of ABCC8 and
KCNJ11 mutations occurs in either a dominant or reces-
sive fashion [1]. Further, depending on inheritance pattern,
these mutations may lead to focal or diffuse disease histo-
logically. Autosomal recessive mutations from both par-
ents typically cause diffuse disease. A paternally-inheritedrecessive mutation in the KATP channel with maternal loss
of heterozygosity leads to paternal uniparental disomy and
the development of focal disease [3, 1]. The genetic results
for this patient demonstrated a paternally-inherited
known pathogenic recessive mutation, but the pathogen-
icity of the maternal mutations was unclear. We have re-
cently learned (from a patient at Children’s Hospital of
Philadelphia) that the W739C maternal variant has been
identified in a patient with diffuse disease indicating that it
likely acts recessively. We suspect the R1393L variant is
pathogenic and could act either recessively or dominantly.
Of note, our patient’s brother is a carrier of the paternal
mutation, but did not inherit either of the maternal muta-
tions. Both of her parents and her brother have no signs
or symptoms of hypoglycemia.
An 18-F-Dopa-PET scan was obtained. This noninva-
sive imaging technique has been used to further delin-
eate between focal and diffuse CHI [19]. However,
diffuse uptake on this scan does not rule out focal dis-
ease [3]. In the largest series, the specificity of this im-
aging technique to detect focal disease was 96 %, with a
positive predictive value of 96 %. In this series, 105 pa-
tients with confirmed CHI underwent pancreatectomy.
Of these, 53 had a postoperative diagnosis of focal CHI.
However, preoperative 18-F-Dopa-PET imaging in 8 of
these 53 was reported erroneously as diffuse [5].
Finally, there are reports of clinical improvement in in-
dividuals with heterozygous ABCC8 mutations [20] or
those with severe disease [21] with time. Whether im-
provement will occur in this patient, remains to be de-
termined, but is becoming less likely. We speculate that
the late presentation of this patient is more likely due to
late detection as opposed to the genetic mutations.
We describe a novel compound heterozygous muta-
tion leading to diffuse, diazoxide-unresponsive CHI. This
case illustrates the pitfalls and challenges associated with
diagnosing CHI and the importance of genetic testing
and how it can guide management decisions, including
whether or not imaging studies are warranted. Lastly,
the case illustrates the difficulty of medically-managing a
patient with diffuse CHI.Consent
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